DE69711897T2 - Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus - Google Patents

Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus

Info

Publication number
DE69711897T2
DE69711897T2 DE69711897T DE69711897T DE69711897T2 DE 69711897 T2 DE69711897 T2 DE 69711897T2 DE 69711897 T DE69711897 T DE 69711897T DE 69711897 T DE69711897 T DE 69711897T DE 69711897 T2 DE69711897 T2 DE 69711897T2
Authority
DE
Germany
Prior art keywords
heparin
chitosan
herpes virus
heparanesulfate
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69711897T
Other languages
English (en)
Other versions
DE69711897D1 (de
Inventor
Olle Larm
Marcus Back
Tomas Bergstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicarb AB
Original Assignee
Medicarb AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicarb AB filed Critical Medicarb AB
Publication of DE69711897D1 publication Critical patent/DE69711897D1/de
Application granted granted Critical
Publication of DE69711897T2 publication Critical patent/DE69711897T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69711897T 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus Expired - Fee Related DE69711897T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning
PCT/SE1997/001320 WO1998005341A1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus

Publications (2)

Publication Number Publication Date
DE69711897D1 DE69711897D1 (de) 2002-05-16
DE69711897T2 true DE69711897T2 (de) 2002-08-22

Family

ID=20403528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69711897T Expired - Fee Related DE69711897T2 (de) 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus

Country Status (13)

Country Link
US (1) US6207653B1 (de)
EP (1) EP0930885B1 (de)
JP (1) JP2000515543A (de)
CN (1) CN1227493A (de)
AT (1) ATE215829T1 (de)
AU (1) AU705189B2 (de)
CA (1) CA2261742A1 (de)
DE (1) DE69711897T2 (de)
DK (1) DK0930885T3 (de)
ES (1) ES2174273T3 (de)
NZ (1) NZ333925A (de)
SE (1) SE507028C2 (de)
WO (1) WO1998005341A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508760C2 (sv) 1997-04-29 1998-11-02 Medicarb Ab Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
AU7070700A (en) * 1999-08-25 2001-03-19 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
EP1774971A1 (de) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Nanopartikel enthaltend Chitosan und Heparin
MX344592B (es) 2005-12-13 2016-12-20 Exthera Medical Corp Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
CL2008000156A1 (es) * 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
CA2763092A1 (en) * 2009-06-10 2010-12-16 Exthera Ab Use of a composition for the treatment of mucositis
AU2010326028B2 (en) 2009-12-01 2014-10-02 Exthera Medical Corporation Method for removing cytokines from blood with surface immobilized polysaccharides
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
CN102858950A (zh) * 2010-04-07 2013-01-02 三菱瓦斯化学株式会社 保存稳定性优异的含有s-腺苷-l-蛋氨酸的干酵母组合物及其制造方法
JPWO2011142484A1 (ja) * 2010-05-14 2013-07-22 株式会社日本触媒 ポリアルキレンイミンを含むウイルス感染症治療薬
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
WO2013188073A1 (en) 2012-06-13 2013-12-19 Exthera Medical, Llc Use of heparin and carbohydrates to treat cancer
WO2014209782A1 (en) 2013-06-24 2014-12-31 Exthera Medical Corporation Blood filtration system containing mannose coated substrate
BR112016009827B1 (pt) 2013-11-08 2021-10-26 Exthera Medical Corporation Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit
JP2017513636A (ja) 2014-04-24 2017-06-01 エクスセラ メディカル コーポレイション 高流量を用いて血液から細菌を除去するための方法
MX2017003723A (es) 2014-09-22 2017-06-30 Exthera Medical Corp Dispositivo de hemoperfusion portatil.
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
US20230381217A1 (en) * 2020-10-14 2023-11-30 Medoderm Gmbh Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease
WO2023044132A2 (en) * 2021-09-17 2023-03-23 Shawn Walker Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) * 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
EP0240098A3 (de) 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
AU1052492A (en) 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent

Also Published As

Publication number Publication date
EP0930885A1 (de) 1999-07-28
SE9602931D0 (sv) 1996-08-06
AU705189B2 (en) 1999-05-20
ATE215829T1 (de) 2002-04-15
AU3791197A (en) 1998-02-25
DE69711897D1 (de) 2002-05-16
EP0930885B1 (de) 2002-04-10
JP2000515543A (ja) 2000-11-21
ES2174273T3 (es) 2002-11-01
DK0930885T3 (da) 2002-05-06
WO1998005341A1 (en) 1998-02-12
SE9602931L (sv) 1998-02-07
US6207653B1 (en) 2001-03-27
CA2261742A1 (en) 1998-02-12
NZ333925A (en) 2000-07-28
SE507028C2 (sv) 1998-03-16
CN1227493A (zh) 1999-09-01

Similar Documents

Publication Publication Date Title
DE69711897D1 (de) Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
CA2194976A1 (en) Wound healing agent
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
DE69428268T2 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
BR9306040A (pt) Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
DE69527765T2 (de) Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE94760T1 (de) Sulfatierte vinylpolymere in praeparaten zur behandlung von retroviralen infektionen.
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
BR9406548A (pt) Composto para emprego como produto farmacêutico composto para emprego no tratamento ou prevenção de câncer e pré-câncer ou de doenças causadas por infecçao viral composto para emprego no tratamento ou prãvençao de câncer ou de pré-câncer composto para emprego no tratamento ou prevenção de doenças causadas por infecção viral composiçao farmacêutica processo para tratar doenças causadas por infecção viral processo de tratamento de câncer ou pré-câncer composto de ácido clorobenzenossulfônico ou ni
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
ATE316789T1 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
DE69428112T2 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
DE69623316T2 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE295159T1 (de) Bupropion zur behandlung von viralen erkrankungen
SE9303612D0 (sv) New use
ATE284209T1 (de) Verwendung einer pharmazeutischen zusammensetzung zur herstellung eines medikamentes zur behandlung von durch bakterien, viren, pilze, hefen und/oder protozoen verursachten augenerkrankungen
EP0342565A3 (de) Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
DE69428797T2 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
DK120892D0 (da) Treatment and prophylaxis of diseases caused by parasites, fungi or bacteria

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee